Aktuellt
SENASTE
Redeye is encouraged by PANTAX phase Ib top-line data aligning with our expectations. We understand that top-line data shows that the trial reached its primary dose-finding endpoint. We leave our estimates and valuation unchanged but will consider an adjustment once the company presents final data and communicates its plans for continued SCO-101 development in pancreatic cancer.
LÄS MER
